Drug interactions

Drug interactions are grouped by mechanism. Pharmacokinetic interactions change how much drug reaches the site of action by altering absorption, distribution, metabolism, or excretion. Pharmacodynamic interactions leave drug levels unchanged but alter the response, either additively — two sedatives producing excessive central nervous system depression — or antagonistically, as when an anticholinergic blunts the effect of a cholinergic agent.

Metabolism is where most clinically important pharmacokinetic interactions arise, largely through the cytochrome P450 enzyme system. An inhibitor such as ketoconazole, clarithromycin, or grapefruit juice slows metabolism of a substrate, raising its concentration and the risk of toxicity. An inducer such as rifampin, carbamazepine, phenytoin, or St. John's wort speeds metabolism, lowering concentrations and potentially causing therapeutic failure — a well-known reason for reduced oral contraceptive effectiveness. Absorption interactions are more mechanical: polyvalent cations in antacids, calcium, and iron chelate tetracyclines and fluoroquinolones, so those products must be separated in time. Displacement from plasma protein binding and competition for renal tubular secretion account for further cases.

Risk rises with the number of medications a patient takes and is greatest for narrow therapeutic index drugs — warfarin, digoxin, lithium, phenytoin, theophylline — where a modest concentration change produces harm. Pharmacy practice manages this through automated screening at order entry, documented allergy and medication histories, and counseling on food, alcohol, and over-the-counter products. Clinically significant alerts must be distinguished from the large volume of low-severity flags.

The PTCE tests drug interactions and contraindications directly, including pharmacokinetic mechanisms and the interaction pairs technicians are expected to recognize. The NCLEX covers adverse effects, contraindications, and interactions within pharmacological and parenteral therapies, and the CCMA covers drug metabolism and action within its pharmacology principles.